Scarica l'app Stockscreener
7.45
8.02%
-0.65
Precedente Chiudi:
$8.10
Aprire:
$8.21
Volume 24 ore:
48,024
Relative Volume:
0.83
Capitalizzazione di mercato:
$23.90M
Reddito:
-
Utile/perdita netta:
$-45.52M
Rapporto P/E:
-0.7659
EPS:
-9.7265
Flusso di cassa netto:
$-31.51M
1 W Prestazione:
-11.31%
1M Prestazione:
-15.44%
6M Prestazione:
+6.43%
1 anno Prestazione:
+1,801%
Intervallo 1D:
$7.20
$8.21
Intervallo di 1 settimana:
$7.20
$9.185
Portata 52W:
$0.257
$20.00
Passage Bio Inc Stock (PASG) Company Profile
Nome
Passage Bio Inc
Settore
Industria
Telefono
(267) 866-0312
Indirizzo
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Compare PASG vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
7.45 | 23.90M | 0 | -45.52M | -31.51M | -9.7265 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-10 | Ripresa | Chardan Capital Markets | Buy |
| 2024-11-29 | Ripresa | Wedbush | Outperform |
| 2024-09-03 | Iniziato | Rodman & Renshaw | Buy |
| 2022-03-08 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-01-19 | Downgrade | Goldman | Buy → Neutral |
| 2021-07-01 | Iniziato | Raymond James | Outperform |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-03-04 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-02-04 | Iniziato | Guggenheim | Buy |
| 2021-01-25 | Iniziato | Wedbush | Outperform |
| 2021-01-04 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-12-11 | Iniziato | Citigroup | Neutral |
| 2020-08-14 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-06-25 | Downgrade | Goldman | Buy → Neutral |
| 2020-03-25 | Iniziato | Chardan Capital Markets | Buy |
| 2020-03-24 | Iniziato | Cowen | Outperform |
| 2020-03-24 | Iniziato | Goldman | Buy |
| 2020-03-24 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Passage Bio Inc Borsa (PASG) Ultime notizie
Aug Retail: Can Passage Bio Inc stock outperform in a bear marketQuarterly Earnings Summary & Verified Technical Signals - baoquankhu1.vn
Passage Bio Ends Hopewell Lab Lease, Extends Cash Runway - TipRanks
Passage Bio (PASG) pays $4.8M to end long-term Hopewell lab lease - Stock Titan
Passage Bio Advances Frontotemporal Dementia Trial and Reports 2025 Results - MyChesCo
Weekly Trades: Is DISTW stock a hidden gemMarket Risk Report & Safe Capital Growth Plans - baoquankhu1.vn
Passage Bio (NASDAQ:PASG) Lowered to Sell Rating by Wall Street Zen - Defense World
Will SBLK stock keep outperforming rivalsPortfolio Value Summary & AI Driven Price Forecasts - Naître et grandir
Portfolio Shifts: Does PRLD have declining or rising EPSTrade Signal Summary & Weekly Top Performers Watchlists - baoquankhu1.vn
Trade Report: What insider trading reveals about Passage Bio Inc. stockPortfolio Profit Report & Precise Entry and Exit Recommendations - Naître et grandir
PASG: Gene therapy for FTD-GRN advances with early-stage focus, strong biomarker data, and regulatory planning - TradingView
PASG: Gene therapy for FTD-GRN advances with safer dosing, strong biomarker data, and regulatory engagement - TradingView
Passage Bio (PASG) Analyst Rating: Canaccord Genuity Lowers Pric - GuruFocus
Passage Bio FY Income from Operations USD -49.296 Million - marketscreener.com
PASG Reports Drop in Cash Reserves for 2025 - GuruFocus
Passage Bio Reports 2025 Results, Advances FTD Program - TipRanks
Passage Bio is actively advancing its differentiated preclinical research project for Huntington's disease. - Bitget
Passage BIO 10-K: Net loss $45.5M; EPS $(14.35) - TradingView
PASG: Net loss narrowed to $45.5M in 2025 as PBFT02 advanced and cash runway extended to Q1 2027 - TradingView
Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights - Bitget
Passage Bio (NASDAQ: PASG) shows strong PBFT02 biomarker gains in FTD - Stock Titan
Passage Bio's 2025 net loss narrows - TradingView
PASG: Clinical progress in FTD and Huntington's, improved financials, and cash runway to 1Q 2027 - TradingView
Passage Bio (NASDAQ: PASG) narrows 2025 loss and advances PBFT02 trial - Stock Titan
Passage Bio Highlights PBFT02 FTD-GRN Biomarker Gains, Targets 2026 Readouts, Runway to Q1 2027 - Defense World
PASG Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
PASG Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Passage Bio Inc expected to post a loss of $2.57 a shareEarnings Preview - TradingView
PASG: Gene therapy for FTD-GRN demonstrates strong biomarker response and safety, with key data due in 2024 - TradingView
Passage Bio management to present at two healthcare conferences - MSN
Passage Bio Management to Present at Two Healthcare Conferences - MyChesCo
Recap Report: Can Passage Bio Inc ride the EV waveQuarterly Risk Review & Safe Entry Point Identification - baoquankhu1.vn
Moving Averages: What is the earnings history of Passage Bio Inc2025 Analyst Calls & Risk Managed Investment Entry Signals - baoquankhu1.vn
Nasdaq Moves: Can Passage Bio Inc. reach all time highs this yearBear Alert & Expert Approved Trade Ideas - mfd.ru
Can Passage Bio Inc. stock hit record highs againInsider Buying & Advanced Technical Analysis Signals - mfd.ru
Passage Bio to Participate in Upcoming Investor Conferences - Caledonian Record
Biotech Passage Bio lines up Oppenheimer and TD Cowen investor talks - Stock Titan
What downside risks could hit Goldman Sachs Equal Weight U.S. stockJuly 2025 Catalysts & Accurate Entry/Exit Alerts - mfd.ru
Can Passage Bio Inc. outperform in the next rallyJuly 2025 Opening Moves & Free Daily Entry Point Trade Alerts - mfd.ru
Will BioMarin Pharmaceutical Inc. (BM8) stock maintain strong growth2025 Earnings Impact & Weekly Chart Analysis and Guides - mfd.ru
Is Passage Bio Inc.’s ROIC above industry averageJuly 2025 Rallies & Entry Point Strategy Guides - mfd.ru
Why Putnam ETF Trust Putnam BioRevolution stock appeals to dividend investorsMarket Volume Summary & Low Risk Growth Stock Ideas - mfd.ru
Buyout Rumor: Should I invest in Passage Bio Inc before earningsInsider Selling & Expert Curated Trade Ideas - baoquankhu1.vn
Passage Bio (NASDAQ:PASG) Coverage Initiated by Analysts at Chardan Capital - Defense World
Brokerages Set Passage Bio, Inc. (NASDAQ:PASG) Target Price at $42.67 - Defense World
Retail Surge: What is the dividend yield of Passage Bio Inc2025 Market Overview & Risk Controlled Swing Alerts - baoquankhu1.vn
Aug Ideas: Can Passage Bio Inc. reach all time highs this yearQuarterly Portfolio Summary & Long-Term Growth Plans - mfd.ru
Gm1 Gangliosidosis Treatment Market Witness Booming Growth: - openPR.com
Earnings Miss: Is PAYC stock a buy or sellTrade Risk Summary & Growth Oriented Trade Recommendations - baoquankhu1.vn
Gap Down: How does Passage Bio Inc perform in inflationary periodsWeekly Stock Summary & Long-Term Investment Growth Plans - baoquankhu1.vn
Aug Analyst Calls: Is Information Services Group Inc likely to announce a buyback2025 Risk Factors & High Conviction Buy Zone Picks - baoquankhu1.vn
Market Rankings: Why is Royce Small Cap Trust Inc stock going downProduct Launch & Low Drawdown Investment Ideas - baoquankhu1.vn
Passage Bio Inc Azioni (PASG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):